Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency.
Aminov S, Giricz O, Melnekoff DT, Sica RA, Polishchuk V, Papazoglu C, Yates B, Wang HW, Sahu S, Wang Y, Gordon-Mitchell S, Leshchenko VV, Schinke C, Pradhan K, Aluri S, Sohn M, Barta SK, Agarwal B, Goldfinger M, Mantzaris I, Shastri A, Matsui W, Steidl U, Brody JD, Shah NN, Parekh S, Verma A. Aminov S, et al. Among authors: melnekoff dt. J Clin Invest. 2024 Feb 20;134(8):e175199. doi: 10.1172/JCI175199. J Clin Invest. 2024. PMID: 38376944 Free PMC article.
Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy.
Van Oekelen O, Nath K, Mouhieddine TH, Farzana T, Aleman A, Melnekoff DT, Ghodke-Puranik Y, Shah GL, Lesokhin A, Giralt S, Thibaud S, Rossi A, Rodriguez C, Sanchez L, Richter J, Richard S, Cho HJ, Chari A, Usmani SZ, Jagannath S, Shah UA, Mailankody S, Parekh S. Van Oekelen O, et al. Among authors: melnekoff dt. Blood. 2023 Feb 16;141(7):756-765. doi: 10.1182/blood.2022017848. Blood. 2023. PMID: 36327160 Free PMC article.
Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma.
Mouhieddine TH, Van Oekelen O, Melnekoff DT, Li J, Ghodke-Puranik Y, Lancman G, Thibaud S, Pan D, Rajeeve S, Agte S, Aleman A, Sanchez L, Richard S, Rossi A, Richter J, Cho HJ, Rodriguez C, Lagana A, Moshier E, Chari A, Jagannath S, Parekh S. Mouhieddine TH, et al. Among authors: melnekoff dt. Blood Adv. 2023 Mar 28;7(6):1056-1064. doi: 10.1182/bloodadvances.2022007923. Blood Adv. 2023. PMID: 36018226 Free PMC article. Clinical Trial.
A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma.
Restrepo P, Bhalla S, Ghodke-Puranik Y, Aleman A, Leshchenko V, Melnekoff DT, Agte S, Jiang J, Madduri D, Richter J, Richard S, Chari A, Cho HJ, Jagannath S, Walker CJ, Landesman Y, Laganà A, Parekh S. Restrepo P, et al. Among authors: melnekoff dt. JCO Precis Oncol. 2022 Jun;6:e2200147. doi: 10.1200/PO.22.00147. JCO Precis Oncol. 2022. PMID: 35704796 Free PMC article.
Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications.
Bhalla S, Melnekoff DT, Aleman A, Leshchenko V, Restrepo P, Keats J, Onel K, Sawyer JR, Madduri D, Richter J, Richard S, Chari A, Cho HJ, Dudley JT, Jagannath S, Laganà A, Parekh S. Bhalla S, et al. Among authors: melnekoff dt. Sci Adv. 2021 Nov 19;7(47):eabg9551. doi: 10.1126/sciadv.abg9551. Epub 2021 Nov 17. Sci Adv. 2021. PMID: 34788103 Free PMC article.
A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma.
Van Oekelen O, Parekh S, Cho HJ, Vishnuvardhan N, Madduri D, Richter J, Ip C, Lau K, Florendo E, Mancia IS, Thomas J, Verina D, Chan E, Zarychta K, La L, Strumolo G, Melnekoff DT, Leshchenko VV, Kim-Schulze S, Couto S, Wang M, Pierceall WE, Thakurta A, Laganà A, Jagannath S, Chari A. Van Oekelen O, et al. Among authors: melnekoff dt. Leuk Lymphoma. 2020 Sep;61(9):2208-2215. doi: 10.1080/10428194.2020.1805111. Epub 2020 Aug 19. Leuk Lymphoma. 2020. PMID: 32812822 Clinical Trial.